^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Yonsa (abiraterone acetate)

    i
    Other names: AAFP, abiraterone acetate fine particle, submicron abiraterone acetate
    Associations

    News

    Trials
    Company:
    Churchill Pharma, Sun Pharma
    Drug class:
    CYP17A1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    15d
    A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (clinicaltrials.gov)
    P=N/A, N=2903, Active, not recruiting, Pfizer | Completed --> Active, not recruiting | N=1800 --> 2903 | Trial completion date: Feb 2024 --> Jan 2025 | Trial primary completion date: Feb 2024 --> Jan 2025
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    Xtandi (enzalutamide) • abiraterone acetate • Erleada (apalutamide) • Yonsa (abiraterone acetate)
    23d
    A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces (clinicaltrials.gov)
    P=N/A, N=1000, Completed, Pfizer | Active, not recruiting --> Completed | Trial completion date: Oct 2024 --> Apr 2024 | Trial primary completion date: Oct 2024 --> Apr 2024
    Trial completion • Trial completion date • Trial primary completion date • Metastases
    |
    Xtandi (enzalutamide) • abiraterone acetate • Erleada (apalutamide) • Yonsa (abiraterone acetate)
    1m
    Study of Relugolix in Men with Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=48, Completed, Sumitomo Pharma Switzerland GmbH | Active, not recruiting --> Completed | N=72 --> 48 | Trial completion date: May 2025 --> May 2024 | Trial primary completion date: May 2025 --> May 2024
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    docetaxel • abiraterone acetate • prednisone • Erleada (apalutamide) • Orgovyx (relugolix) • Yonsa (abiraterone acetate)
    2ms
    REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial (clinicaltrials.gov)
    P3, N=72, Not yet recruiting, Emory University
    New P3 trial • Metastases
    |
    abiraterone acetate • bicalutamide • Orgovyx (relugolix) • leuprolide acetate for depot suspension • Yonsa (abiraterone acetate)
    3ms
    Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Oct 2024 --> Oct 2026 | Trial primary completion date: Oct 2024 --> Oct 2026
    Trial completion date • Trial primary completion date • Metastases
    |
    abiraterone acetate • Erleada (apalutamide) • Yonsa (abiraterone acetate)
    3ms
    Study of Relugolix in Men with Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=72, Active, not recruiting, Sumitomo Pharma Switzerland GmbH | Trial completion date: May 2024 --> May 2025 | Trial primary completion date: May 2024 --> May 2025
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    docetaxel • abiraterone acetate • prednisone • Erleada (apalutamide) • Orgovyx (relugolix) • Yonsa (abiraterone acetate)
    6ms
    A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (clinicaltrials.gov)
    P=N/A, N=1800, Completed, Pfizer | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Feb 2024 | Trial primary completion date: Dec 2024 --> Feb 2024
    Trial completion • Trial completion date • Trial primary completion date • Metastases
    |
    Xtandi (enzalutamide) • abiraterone acetate • Erleada (apalutamide) • Yonsa (abiraterone acetate)
    7ms
    A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov)
    P=N/A, N=2800, Active, not recruiting, Pfizer | Trial completion date: Mar 2024 --> Dec 2024 | Trial primary completion date: Mar 2024 --> Dec 2024
    Trial completion date • Trial primary completion date • Real-world evidence • Real-world • Metastases
    |
    Xtandi (enzalutamide) • abiraterone acetate • Yonsa (abiraterone acetate)
    7ms
    Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=72, Active, not recruiting, Sumitomo Pharma Switzerland GmbH | Recruiting --> Active, not recruiting | Trial completion date: Nov 2023 --> May 2024 | Trial primary completion date: Jan 2023 --> May 2024
    Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    docetaxel • abiraterone acetate • prednisone • Erleada (apalutamide) • Orgovyx (relugolix) • Yonsa (abiraterone acetate)
    8ms
    ACTIon: Abiraterone Acetate in Combination With Tildrakizumab (clinicaltrials.gov)
    P1/2, N=13, Terminated, Institute of Cancer Research, United Kingdom | Trial completion date: Oct 2024 --> Nov 2023 | Active, not recruiting --> Terminated; Funder decided that response outcomes to date did not support continuation of the study.
    Trial completion date • Trial termination • Combination therapy • Metastases
    |
    IL23A (Interleukin 23 Subunit Alpha)
    |
    Ilumya (tildrakizumab-asmn) • Yonsa (abiraterone acetate)
    8ms
    Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment Prostate Cancer (clinicaltrials.gov)
    P2, N=64, Recruiting, Mayo Clinic | Not yet recruiting --> Recruiting
    Enrollment open
    |
    abiraterone acetate • Yonsa (abiraterone acetate)
    8ms
    Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment Prostate Cancer (clinicaltrials.gov)
    P2, N=64, Not yet recruiting, Mayo Clinic
    New P2 trial
    |
    abiraterone acetate • Yonsa (abiraterone acetate)
    10ms
    A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces (clinicaltrials.gov)
    P=N/A, N=1000, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    Xtandi (enzalutamide) • abiraterone acetate • Erleada (apalutamide) • Yonsa (abiraterone acetate)
    10ms
    NCI-2018-01054: Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=7, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Apr 2024 --> Apr 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    PTEN (Phosphatase and tensin homolog)
    |
    AR overexpression • AR expression • AR-V7 expression
    |
    abiraterone acetate • Erleada (apalutamide) • Yonsa (abiraterone acetate)
    10ms
    Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer (clinicaltrials.gov)
    P2, N=7, Active, not recruiting, OHSU Knight Cancer Institute | Trial completion date: Jan 2026 --> Jan 2030 | Trial primary completion date: Jan 2024 --> Jan 2028
    Trial completion date • Trial primary completion date • Metastases
    |
    docetaxel • abiraterone acetate • Erleada (apalutamide) • Yonsa (abiraterone acetate)
    10ms
    A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov)
    P=N/A, N=2800, Recruiting, Pfizer | Active, not recruiting --> Recruiting
    Enrollment open
    |
    Xtandi (enzalutamide) • abiraterone acetate • Yonsa (abiraterone acetate)
    11ms
    Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose. (clinicaltrials.gov)
    P1, N=50, Active, not recruiting, University of Chicago | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    abiraterone acetate • Yonsa (abiraterone acetate)
    11ms
    Study of MK-5684 Versus Alternative NHA in mCRPC (MK-5684-003) (clinicaltrials.gov)
    P3, N=1200, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting | Trial completion date: Jun 2029 --> Aug 2028
    Enrollment open • Trial completion date • Metastases
    |
    AR mutation
    |
    Xtandi (enzalutamide) • abiraterone acetate • prednisone • dexamethasone • opevesostat (MK-5684) • Yonsa (abiraterone acetate)
    12ms
    Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer (clinicaltrials.gov)
    P2, N=70, Recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Aug 2027 | Trial primary completion date: Dec 2023 --> Aug 2027
    Trial completion date • Trial primary completion date
    |
    Talzenna (talazoparib) • abiraterone acetate • Eligard (leuprolide acetate) • bicalutamide • goserelin acetate • Firmagon (degarelix) • Viadur (leuprorelin implant) • Yonsa (abiraterone acetate)
    12ms
    A Study of MK-5684 Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) (clinicaltrials.gov)
    P3, N=1500, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    Xtandi (enzalutamide) • abiraterone acetate • prednisone • dexamethasone • opevesostat (MK-5684) • Yonsa (abiraterone acetate)
    12ms
    A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces (clinicaltrials.gov)
    P=N/A, N=1000, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Xtandi (enzalutamide) • abiraterone acetate • Erleada (apalutamide) • Yonsa (abiraterone acetate)
    1year
    A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov)
    P=N/A, N=2800, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Xtandi (enzalutamide) • abiraterone acetate • Yonsa (abiraterone acetate)
    1year
    A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (clinicaltrials.gov)
    P=N/A, N=1800, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Xtandi (enzalutamide) • abiraterone acetate • Erleada (apalutamide) • Yonsa (abiraterone acetate)
    1year
    A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces (clinicaltrials.gov)
    P=N/A, N=1000, Not yet recruiting, Pfizer
    New trial
    |
    Xtandi (enzalutamide) • abiraterone acetate • Erleada (apalutamide) • Yonsa (abiraterone acetate)
    1year
    Study of MK-5684 Versus Alternative NHA in mCRPC (MK-5684-003) (clinicaltrials.gov)
    P3, N=1200, Not yet recruiting, Merck Sharp & Dohme LLC
    New P3 trial • Metastases
    |
    Xtandi (enzalutamide) • abiraterone acetate • prednisone • dexamethasone • opevesostat (MK-5684) • Yonsa (abiraterone acetate)
    1year
    A Study of MK-5684 Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) (clinicaltrials.gov)
    P3, N=1500, Not yet recruiting, Merck Sharp & Dohme LLC
    New P3 trial • Metastases
    |
    Xtandi (enzalutamide) • abiraterone acetate • prednisone • dexamethasone • opevesostat (MK-5684) • Yonsa (abiraterone acetate)
    1year
    A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (clinicaltrials.gov)
    P=N/A, N=1, Recruiting, Pfizer | Not yet recruiting --> Recruiting | N=1800 --> 1
    Enrollment open • Enrollment change • Metastases
    |
    Xtandi (enzalutamide) • abiraterone acetate • Erleada (apalutamide) • Yonsa (abiraterone acetate)
    1year
    A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (clinicaltrials.gov)
    P=N/A, N=1800, Not yet recruiting, Pfizer
    New trial • Metastases
    |
    Xtandi (enzalutamide) • abiraterone acetate • Erleada (apalutamide) • Yonsa (abiraterone acetate)
    1year
    Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Oct 2023 --> Oct 2024 | Trial primary completion date: Oct 2023 --> Oct 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    AR (Androgen receptor) • PD-1 (Programmed cell death 1)
    |
    abiraterone acetate • Erleada (apalutamide) • Yonsa (abiraterone acetate)
    over1year
    NCI-2018-01054: Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=7, Active, not recruiting, M.D. Anderson Cancer Center | Suspended --> Active, not recruiting | N=60 --> 7
    Enrollment closed • Enrollment change • Metastases
    |
    PTEN (Phosphatase and tensin homolog)
    |
    AR overexpression • AR expression • AR-V7 expression
    |
    abiraterone acetate • Erleada (apalutamide) • Yonsa (abiraterone acetate)
    over1year
    ACTIon: Abiraterone Acetate in Combination With Tildrakizumab (clinicaltrials.gov)
    P1/2, N=13, Active, not recruiting, Institute of Cancer Research, United Kingdom | Recruiting --> Active, not recruiting | N=55 --> 13 | Trial primary completion date: Oct 2023 --> Apr 2023
    Enrollment closed • Enrollment change • Trial primary completion date • Combination therapy • Metastases
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • PTEN (Phosphatase and tensin homolog) • AR (Androgen receptor) • IL23A (Interleukin 23 Subunit Alpha)
    |
    Ilumya (tildrakizumab-asmn) • Yonsa (abiraterone acetate)
    almost2years
    NCI-2018-01054: Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=60, Suspended, M.D. Anderson Cancer Center | Trial completion date: Oct 2022 --> Apr 2024 | Trial primary completion date: Oct 2022 --> Apr 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    PTEN (Phosphatase and tensin homolog)
    |
    AR overexpression • AR expression • AR-V7 expression
    |
    abiraterone acetate • Erleada (apalutamide) • Yonsa (abiraterone acetate)
    almost2years
    Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Oct 2022 --> Oct 2023
    Trial primary completion date • Metastases
    |
    AR (Androgen receptor) • PD-1 (Programmed cell death 1)
    |
    abiraterone acetate • Erleada (apalutamide) • Yonsa (abiraterone acetate)
    almost2years
    NCI-2018-01548: Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer (clinicaltrials.gov)
    P2, N=11, Terminated, University of Washington | Active, not recruiting --> Terminated; Terminated due to low accrual.
    Trial termination
    |
    CCR7 (Chemokine (C-C motif) receptor 7)
    |
    abiraterone acetate • prednisone • Yonsa (abiraterone acetate)
    2years
    Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer (clinicaltrials.gov)
    P2, N=70, Recruiting, City of Hope Medical Center | Active, not recruiting --> Recruiting | N=20 --> 70
    Enrollment open • Enrollment change
    |
    AR (Androgen receptor)
    |
    Talzenna (talazoparib) • abiraterone acetate • Eligard (leuprolide acetate) • bicalutamide • goserelin acetate • Firmagon (degarelix) • Viadur (leuprorelin implant) • Yonsa (abiraterone acetate)
    2years
    Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting | N=70 --> 20
    Enrollment closed • Enrollment change
    |
    AR (Androgen receptor)
    |
    Talzenna (talazoparib) • abiraterone acetate • Eligard (leuprolide acetate) • bicalutamide • goserelin acetate • Firmagon (degarelix) • Viadur (leuprorelin implant) • Yonsa (abiraterone acetate)
    over2years
    NCI-2018-01548: Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer (clinicaltrials.gov)
    P2, N=11, Active, not recruiting, University of Washington | Trial completion date: Nov 2023 --> Feb 2023 | Trial primary completion date: Sep 2023 --> Sep 2022
    Trial completion date • Trial primary completion date
    |
    CCR7 (Chemokine (C-C motif) receptor 7)
    |
    abiraterone acetate • prednisone • Yonsa (abiraterone acetate)
    over2years
    Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    AR (Androgen receptor) • PD-1 (Programmed cell death 1)
    |
    abiraterone acetate • Erleada (apalutamide) • Yonsa (abiraterone acetate)
    over2years
    NCI-2018-01548: Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer (clinicaltrials.gov)
    P2, N=11, Active, not recruiting, University of Washington | Recruiting --> Active, not recruiting | N=30 --> 11
    Enrollment closed • Enrollment change
    |
    CCR7 (Chemokine (C-C motif) receptor 7)
    |
    abiraterone acetate • prednisone • Yonsa (abiraterone acetate)
    over2years
    NCI-2018-01054: Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=60, Suspended, M.D. Anderson Cancer Center | Trial completion date: Oct 2021 --> Oct 2022 | Trial primary completion date: Oct 2021 --> Oct 2022
    Trial completion date • Trial primary completion date
    |
    PTEN (Phosphatase and tensin homolog)
    |
    AR overexpression • AR expression • AR-V7 expression
    |
    abiraterone acetate • Erleada (apalutamide) • Yonsa (abiraterone acetate)
    3years
    NCI-2018-01548: Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer (clinicaltrials.gov)
    P2, N=30, Recruiting, University of Washington | Trial completion date: Nov 2022 --> Nov 2023 | Trial primary completion date: Sep 2022 --> Sep 2023
    Clinical • Trial completion date • Trial primary completion date
    |
    CCR7 (Chemokine (C-C motif) receptor 7)
    |
    abiraterone acetate • prednisone • Yonsa (abiraterone acetate)
    over3years
    Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer (clinicaltrials.gov)
    P2, N=70, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
    Enrollment open • Trial completion date • Trial primary completion date
    |
    AR (Androgen receptor)
    |
    Talzenna (talazoparib) • abiraterone acetate • Eligard (leuprolide acetate) • bicalutamide • goserelin acetate • Firmagon (degarelix) • Viadur (leuprorelin implant) • Yonsa (abiraterone acetate)